^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

TAC01-CD19

i
Other names: TAC01-CD19, CD19 TAC, CD19-TAC01, TAC-921
Associations
Company:
Triumvira
Drug class:
CD19 inhibitor
Associations
over2years
TACTIC-19: Autologous TAC T Cells Targeting CD19 in R/R Large B-Cell Lymphoma (clinicaltrials.gov)
P1/2, N=0, Withdrawn, Triumvira Immunologics, Inc. | N=36 --> 0 | Not yet recruiting --> Withdrawn
Enrollment change • Trial withdrawal
|
BCL2 (B-cell CLL/lymphoma 2) • CD19 (CD19 Molecule) • BCL6 (B-cell CLL/lymphoma 6)
|
BCL6 rearrangement • BCL2 rearrangement
|
TAC01-CD19
over4years
TACTIC-19: Autologous TAC T Cells Targeting CD19 in R/R Large B-Cell Lymphoma (clinicaltrials.gov)
P1/2, N=36, Not yet recruiting, Triumvira Immunologics, Inc. | Trial completion date: Dec 2023 --> Apr 2024 | Trial primary completion date: Dec 2021 --> Apr 2022
Clinical • Trial completion date • Trial primary completion date
|
BCL2 (B-cell CLL/lymphoma 2) • CD19 (CD19 Molecule) • BCL6 (B-cell CLL/lymphoma 6)
|
BCL6 rearrangement • BCL2 rearrangement
|
TAC01-CD19